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Abstract
Background and objective: Aortic stenosis is a highly prevalent and life-threatening disease. In 
elderly patients with comorbidities, percutaneous valve implantation is an option. The aim of the 
study was to describe the anesthetic management and complications of general anesthesia. 
Method: Case series with 30-day and 24-month follow-ups after implantation of the CoreValve 
device performed at the Institute of Cardiology/University Foundation of Cardiology between 
December 2008 and January 2012. The patients underwent general anesthesia monitored 
with mean arterial pressure (PAM), electrocardiogram (ECG), pulse oximetry, capnography, 
transesophageal echocardiography, thermometry, and transvenous pacemaker.
Results: Twenty-eight patients, mean age 82.46 years, 20.98% mean EuroSCORE, functional class 
III/IV, successfully underwent valve implantation. Nine patients required permanent pacemaker 
implantation. During follow-up, two patients died: one during surgery due to LV perforation and 
the other on the third day of unknown causes. At 24 months, one patient diagnosed with multiple 
myeloma died. This anesthetic technique proved to be safe. 
Conclusion: The initial experience with percutaneous aortic valve implantation under general 
anesthesia has proven to be safe and effective, with no signiﬁ cant anesthetic complications 
during this procedure. 
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Introduction
Aortic stenosis (AS) is the most common valvular heart di-
sease. It is insidious, has a long period of latency, followed 
by rapid progression after the onset of symptoms, resulting 
in high mortality among untreated patients 1. Aortic valve 
replacement is the treatment of choice for symptomatic 
AS. However, according to the Euro Heart Survey on Valvular 
Disease 2, one third of these patients is aged over 75 years 
and has contraindications for conventional surgery. In recent 
years, percutaneous aortic valve implantation has emerged 
as a viable and promising treatment option. This new thera-
peutic approach is designed for patients who have no medical 
conditions to undergo the classical surgical approach due 
to the high or unacceptable risk of perioperative morbidity 
and mortality.
Aortic valve replacement via percutaneous route is a new 
treatment option for these patients, ﬁ rst used in humans by 
Cribier et al. 3 in 2002. Since then, several clinical trials with 
different devices have been reported 4.
There are currently two types of prostheses for clini-
cal use: CoreValve (Medtronic Inc., Minneapolis, MN) and 
Edwards-Sapien (Edwards Life Sciences Inc., Irvine, CA) 3,5-7. 
Ideally, these procedures would involve a multidisciplinary 
team and be performed in hybrid operating rooms. The hybrid 
room is a more appropriate space for this purpose because it 
is larger, has better monitoring, and facilitates migration to 
a surgical event requiring cardiopulmonary bypass.
The anesthetic technique for percutaneous valve implan-
tation is yet to be decided between deep sedation and gene-
ral anesthesia. To choose the best anesthetic technique, the 
patient’s comfort and immobility at important times of the 
procedure, the physical area restriction, and the involvement 
of various professionals should all be considered.
The objective of this study was to describe the anesthetic 
technique and complications in patients undergoing percuta-
neous valve implantation under general anesthesia.
Method
Longitudinal descriptive study of 28 patients undergoing 
percutaneous valvular aortic implantation with the CoreValve 
device in the Institute of Cardiology of Rio Grande do Sul 
from December 2008 to January 2012. The institution’s Ethics 
Committee approved the study. 
All patients were visited the day before surgery. After 
receiving guidance and getting their doubts cleared, all 
participants signed an informed consent term. The patients 
underwent 8-hour fasting and received no premedication. 
Preoperatively, two units of blood cells, plasma, and platelets 
were reserved and adequate hydration prepared, especially 
for patients with chronic renal failure.
Monitoring was performed with two-lead ECG (II and 
V5), invasive blood pressure, central venous pressure, pulse 
oximetry, capnography, temporary pacemaker with electrode 
placement in right ventricule (RV) for maintaining a rapid rate 
at the time of angioplasty, bladder catheterization, transe-
sophageal echocardiography (TEE), and thermometry. 
As routine procedure, we used intravenous (IV) midazolam 
2 mg and induced the anesthesia with etomidate 0.2 mg.kg-1; 
tracheal intubation was preceded by neuromuscular blocking 
agent (atracurium 0.5 mg.kg-1 or rocuronium 0.5 mg.kg-1); 
analgesia was performed with continuous intravenous remi-
fentanil 0.2 mcg.kg.-1.min-1 and maintenance with sevoﬂ u-
rane. As inotropic and vasopressor, we used norepinephrine 
through infusion pump and/or araminol and adrenaline, if 
necessary. All patients underwent oral intubation and con-
trolled mechanical ventilation.
After induction, catheterization of the right subclavian 
vein was performed with double-lumen catheter and right 
internal jugular vein with 7-French introducer, with endoca-
vitary pacemaker electrode placed in the right ventricle. 
Heparin 100 UI.kg-1 was administered intravenously 
to maintain an activated clotting time between 200-250 
seconds and protamine used for reversal at the end of the 
procedure.
Study design and selection criteria
All cases were evaluated by a multidisciplinary team 
composed of one interventional cardiologist, one clinical 
cardiologist, one cardiac surgeon, one anesthesiologist 
with experience in cardiology that considered the stan-
dard valvular replacement technique of high periopera-
tive risk, with great potential for mortality and possible 
complications.
Inclusion criteria were: patients with severe aortic steno-
sis (valve area ≤ 1 cm²), age ≥ 75 years, Euro SCORE ≥ 20%, 
aorto-ventricular gradient ≥ 40 mm Hg, or with high surgical 
risk. Additionally, some of the following symptoms needed to 
be present: chest pain or limiting dyspnea, dizziness, pre-
syncope or syncope, and ventricular arrhythmia. Exclusion 
criteria were: patients with unfavorable anatomy for implan-
tation, impossibility of vascular access, blood dyscrasias, 
systemic disease with life expectancy less than one year, and 
those who refused to undergo the procedure 8.
Screening of patients involved the assessment of anatomi-
cal and functional conditions favorable for valve implantation 
of CoreValve. We performed a transthoracic echocardiography 
(TEE) with color Doppler and cineangiocoronarygraphy. We 
performed a multi-detector angiotomography when there was 
doubt about the measures provided by other tests. Clinical 
and angiographic data were included in forms according to 
the manufacturer’s standard assessment protocol, which 
determined inclusion of patients in the study. 
Procedure description 
We used a third generation CoreValve aortic valve prosthesis, 
which consists of a bioprosthesis of three porcine pericardium 
leaﬂ ets mounted and sutured in a self-expanding nitinol 
stent (Figure 1). The smallest inner diameter of the valve is 
21 mm and its structure (nitinol stent) is laser cut in a tube 
50 mm long. 
The prosthesis distal portion has high radial force, which 
allows its expansion and exclusion from the already calci-
ﬁ ed native valve leaﬂ ets, preventing its retraction after 
implantation. The middle portion carries the valve and its 
architecture allows the coronary ostia to be free and acces-
sible. The proximal portion is enlarged, allowing its ﬁ xation 
and longitudinal stability. Before implantation, the valve 
is washed and cooled in cold saline solution, undergoes a 
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series of vascular molds to reduce its proﬁ le and is ﬁ xed at 
an 18-French delivery system, releasing the prosthesis after 
balloon valvuloplasty (Figure 2).
All patients received AAS 500 mg and clopidogrel 300 mg 
the day before surgery. The vascular access for prosthesis 
introduction was made by puncture or dissection of the iliac 
or common femoral artery.
At the beginning of the procedure, a temporary pace-
maker electrode was introduced into the RV through the right 
internal jugular and used to prevent bradycardia and increase 
heart rate (rapid pacing) to prevent balloon migration at the 
time of valvuloplasty, preceding the prosthesis release 9,10.
We continuously evaluated patients’ clinical and hemody-
namic parameters during the procedure. We took contrasted 
aortographies before, during, and after valve implantation 
to better aid prosthesis positioning and release and assess 
leakage or residual aortic regurgitation. Transesophageal 
echocardiography was used to see the immediate results and, 
if necessary, for reintervention to improve the adequacy of 
the prosthetic valve.
The puncture or dissection area was inﬁ ltrated with local 
anesthetic (bupivacaine 0.5% or ropivacaine 0.75%), as well 
as at the end of the procedure, to minimize postoperative 
pain. We kept the temporary pacemaker until discharge from 
the postoperative unit (POU).
We performed a transthoracic echocardiography before 
hospital discharge, and recommended the use of AAS 100 
mg.day-1 and clopidogrel 75 mg.day-1 for at least six months.
Results
From December 2008 to January 2012, 28 patients with 
severe aortic stenosis who were not candidates for surgery 
underwent percutaneous aortic valve implantation. All pa-
tients were followed-up for up to 24 months.
As for transcatheter valve replacement, the VARC 
(Valve Academie Consortion Research) was created with the 
participation of experts, members of the Food and Drugs 
Administration (FDA), and industry representatives who es-
tablished a table with the success rate in percutaneous valve 
implantation, which we used in our patients 11 (Table 1). 
Figure 1  Bioprosthesis of three porcine pericardium leaﬂ ets 
mounted and sutured in a self-expanding nitinol stent.
Figure 2  18-French prosthesis delivery system.
Table 1  VARC* Criteria: success and adverse events.
n (%)
Number of patients 28
Implant success 23 (82.14%)
Death (CV) 3 (10.71%)
Death (any cause) 4 (14.29%)
AMI during procedure 1 (3.37%)
Spontaneous AMI 0
CVA 4 (14.29%)
Hemorrhagic complication
Risk of death 1 (3.57%)
Major bleeding 6 (21.43%)
Minor bleeding 2 (7.14%)
ARF
Stage I 3 (10.71%)
Stage II 2 (7.14%)
Stage III 0
Vascular complication
Major 3 (10.71%)
Minor 2 (7.14%)
Bioprosthesis dysfunction 0
Complication associated with bioprostheses
Contiguity 14 (50%)
Endocarditis 0
Hemolysis 0
Complications related to the implant 5        (17.86%)
*Valve Academic Research Consortium; CV: cardiovascular; AMI: 
acute myocardial infarction; CVA: cerebrovascular accident; 
ARF: acute renal failure.
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Of all patients, 80% were admitted to the catheteriza-
tion laboratory with hypertension and heart rate between 
60-70 bpm. This hypertension upon arrival at the laboratory 
was probably due to their stress from the procedure and 
the absence of sedation pre-anesthesia. Anxiety was easily 
treated using intravenous midazolam. After anesthetic 
induction, tension decreased by about 20%, and patients 
remained stable throughout the procedure with low doses 
of vasopressors or noradrenaline. Noradrenaline (8 mg) was 
prepared with saline solution (192 mL). All patients received 
noradrenaline as tensional support at low doses of 0.03-0.05 
μg.kg.-1min-1. At the end of the procedure, no patient took 
noradrenaline for support.
The mean time of anesthesia was 162 minutes. Ninety 
percent of all patients were anemic, with mean hemoglo-
bin of 9.2 g%. Total blood loss was minimal, but 18.80% of 
patients required transfusion at the end of the procedure 
(three patients received one red blood cell concentration 
[RBCC] and one patient received two RBCC). At the end of 
surgery, the patients underwent aspiration, decurarization 
if necessary, and extubation. They were taken awake and 
spontaneously breathing with oxygen catheter to the reco-
very room. The exception was one patient who underwent 
surgery with cardiopulmonary bypass and had ventricular 
perforation, evolving to death.
The anesthetic technique proved to be safe. Anesthesia 
was uneventful. We easily corrected initial hypotension with 
vasopressor, hemodynamic stability maintained throughout 
the procedure with continuous norepinephrine and extrasys-
toles, resulting from catheter handling inside the heart. 
There was no need for correction with drugs and the patient 
was discharged awake.
Table 2 shows the demographic characteristics, risk 
factors and logistic EuroSCORE of the patients in our case 
series.
After the transcatheter aortic valve implantation (TAVI), 
patients were assessed and showed immediate improvement 
in cardiac functional patterns, with decreased pressure gra-
dient between the left ventricle and aorta. Table 3 shows 
the characteristics after implantation.
After implantation, the New York Heart Association 
(NYHA) classiﬁ cation of functional capacity changed to I and 
II in 90% of cases. Aortic-ventricular gradients decreased from 
54.89 mm Hg to 9.3 mm Hg in the immediate postoperative 
period, 9.2 in 30 days, 10.3 in six months, and 12.8 in one 
year. The mean valve area, which preoperatively was 0.61 
cm, changed to 1.53 in 30 days and 1.54 in six months and 
one year.
Among the 28 patients who received percutaneous aortic 
valve with the CoreValve device, three of them died: one 
during surgery due to left ventricule (LV) perfuration, one 
in 72 hours of unknown cause, and one in 12 months with 
a diagnosis of multiple myeloma. All other patients were 
discharged without any complications from anesthesia.
Six patients were readmitted and treated for massive 
epistaxis, pneumonia, fully recovered cerebrovascular ac-
cident, endovascular repair of iliac laceration, and embo-
lectomy of the right leg. They were subsequently released 
for follow-up. There were no other complications, and all 
patients progressed well, with improvement of symptoms 
and clinical stability.
Among evaluated patients, nine (45%) required a perma-
nent pacemaker due to complete AV block (CAVB) and one due 
to chronic auricular ﬁ brillation (CAF) with low ventricular res-
ponse, implanted postoperatively between days 0 and 15.
When ECG changes occurred (CAVB) during the valve 
release, two-thirds of these patients progressed to a per-
manent pacemaker. The use of general anesthesia proved to 
be safe, with no neurological or hemodynamic consequences 
postoperatively.
During medium and long-term follow-up, the pressure 
gradients remained similar to that at hospital discharge. 
Ventricular function remained preserved with decreased mus-
cle mass, and there was no signiﬁ cant aortic regurgitation.
Discussion
Percutaneous valve implantation with the CoreValve device 
proved to be an important option for reducing the transval-
vular aortic gradient of patients undergoing this procedure 
(Figure 3). The anesthetic technique remains uncertain, as 
there are schools using the deep sedation technique, others 
using general anesthesia, and still another school using com-
bined epidural anesthesia with sedation 4,12-16.
General anesthesia and deep sedation have been used in 
several studies with good results 4,10,16-27. In our case series, 
we used general anesthesia due to the need for prolonged 
immobilization of patients in uncomfortable tables, ten-
dency for hypothermia, the team’s learning curve, need for 
surgical repair of catheterized arteries, TEE use, possibility 
of neurological complications and surgical intervention with 
cardiopulmonary bypass (CPB), and little knowledge on the 
technique. Hemodynamic stability was the main goal of the 
anesthetic management - low heart rate (50-70 bpm) was 
preferable - and supraventricular and ventricular arrhyth-
mias were managed aggressively and reversal achieved. 
Hypotension was quickly treated with araminol bolus or 
continuous noradrenaline. 
Complications related to percutaneous implantation are 
mainly vascular and directly associated with the diameter 
of catheters used. Cerebrovascular accident (CVA) resulting 
from embolization of friable native valve material is an event 
occurring in approximately 18% of patients 12,28,29. Acute renal 
failure (ARF) occurs in 12-28% of cases 30-32. A limited clinical 
experiment suggests that the renal function often improves 
with the best cardiac output after AE correction. ARF is 
usually mild and easily reversed and less common than in 
surgical patients 33. Coronary obstruction rarely occurs and is 
a result of the native valve displacement of the left coronary 
ostium. This complication can be managed conservatively 30. 
Conduction system injury occurs in the interventricular sep-
tum below the aortic valve, causing a bundle branch block 
and/or complete AV block, with an incidence of permanent 
pacemaker implantation in 3-36%, with an additional risk 
factor for elderly patients with previous blocks 12,34,35. The 
result was superior those in the literature, with an incidence 
between 9-36% of patients 12.36. One reason for this is that 
the stent compresses the valve annulus and surrounding 
structures, including components of the electrical conduction 
system of the heart. The AV node and left branch of the His 
bundle travels inside the ﬁ brous body near the aortic valve 
non-coronary cusp, and may be affected by the device or 
swelling structures 12,37. According to literature, left bundle 
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block may occur in up to 33% of cases and is associated with 
worse prognosis. The need for permanent pacemaker varies 
between 3-40%. Our complications can be compared by VARC 
criteria (Table 2). One-third of patients undergoing CoreValve 
implantation requires permanent pacemaker in 30 days, 
compared to conventional surgery, which is < 10%.
Among the probable factors, we can mention atrio-
ventricular block during the procedure, pre-dilatation 
with balloon, prosthesis size, interventricular septum 
increased diameter, prolonged QRS duration, and team 
experience 38-40. 
Table 2  Patients’ Characteristics and Comorbidities.
Patient Sex Age EuroScore Comorbidity Class F. NYHA Prior MP 
1 F 90 9 SAH IV N
2 F 80 19 IHD, CABG, SAH III N
3 F 85 20 Gastrectomy IV N
4 F 86 11 IHD + LBB II N
5 M 94 34 IHD, CVA, PAH IV N
6 F 99 33 IHD, DM, SAH II N
7 M 8 9 IHD, CRF, DM III N
8 F 76 9.8 IHD, SAH, CAVB II N
9 F 90 10.7 IHD, SAH, CABG, PAH III N
10 F 80 12 SAH, DSL II N
11 F 88 46 SAH III N
12 F 87 12 COPD, CAVB II N
13 F 79 26 IHD, CAVB, COPD II N
14 F 85 16.2 SAH II N
15 M 82 17.2 SAH, CRF, Myeloma III S
16 M 87 46 IHD, CABG, CAVB, HIV III S
17 F 83 13.8 IHD, SAH IV N
18 M 89 62.9 SAH, COPD IV S
19 M 79 32.8 COPD, IHD III N
20 M 62 8.9 IHD, CAVB, CRF, Hepat III S
21 M 65 32 IHD, COPD, CVA II N
22 M 64 8.1 IHD, SAH, CABG II N
23 M 83 6.6 IHD, Prostate cancer II N
24 F 92 16 CAVB, CR III N
25 F 80 21.3 COPD, DC, PVD III N
26 M 89 17.8 SAH, AAA, DLP III N
27 M 68 2.7 Esophageal cancer, QT, RTx IV S
28 F 85 10.7 SAH, Bronchitis III N
SAH: systemic arterial hypertension, IHD: ischemic heart disease, CABG: coronary artery bypass graft surgery; LBB: left bundle 
block, CVA: cerebrovascular accident; PAH: pulmonary arterial hypertension, DM: diabetes mellitus, CRF: chronic renal failure; 
CAAF: complete arrhythmia due to atrial ﬁ brillation; COPD: chronic obstructive pulmonary disease; CAVB: complete AV block, AAA: 
abdominal aortic aneurysm, QT: chemotherapy; DSL: dyslipidemia; PVD: peripheral vascular disease.
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This study has some limitations such as having no con-
trol group, the sampling was small, highly selective with 
patients pertaining to a single center with no correlation to 
other types of anesthesia (e.g., deep sedation), which may 
represent a local reality.
One issue that should be considered for percutaneous 
aortic valve implantation, which remains open at the 
present stage of knowledge, is the CoreValve prosthesis 
durability over the years, as the natural history of the 
biological and metal prostheses implanted by conventional 
surgery is well known 28. Regarding analysis of gradients 
and valve area, several studies suggest that the percu-
taneous prostheses currently used have a performance 
Table 3  Patients’ Characteristics Pre- and Post-implantation.
Patient Area (pre) (cm²) Area (post) (cm²) Transvalvular 
gradient (pre)
Transvalvular 
gradient (post)
Transvalvular 
gradient  (post) 6m
1 0.46 1.54 88 9 9.7
2 0.63 ND 45 13.1 11
3 0.4 1.44 98 14.7 10.7
4 0.65 1.9 56 10.5 9
5 0.7 ND 53 6 6
6 0.5 1.41 65 11 15
7 0.7 ND 82 8.8 8
8 0.75 1.4 49 5.6 12
9 0.79 1.48 45 5.6 9
10 0.73 1.42 55 12.7 13
11 0.95 95
12 0.47 47
13 0.73 1.8 42 12. 2
14 0.45 1.8 62 9
15 ND 1.7 40 11
16 ND ND 32 11 15
17 0.65 1.56 35
18 0.85 2.1 44 5
19 0.69 2.4 54 5.1
20 0.6 32
21 0.64 31
22 40 8
23 0.6 1.8 63 11
24 0.94 1.81 51 3
25 0.7 1.32 40 13
26 0.7 1.5 55 5  
comparable to that of surgical prostheses 12. Therefore, 
a multidisciplinary team should evaluate patients TIVA 
indication.
New valves are emerging that provide greater safety and 
effectiveness for a procedure that has already been showing 
good results. Other valves are being clinically evaluated, 
which will incorporate other means to facilitate proper po-
sitioning and reduce paravalvular leaks. The new generation 
of valves with greater expansion force may dismiss the use 
of the balloon and favor valve ﬁ xation 41. Although these 
valves are contributing to the treatment of aortic stenosis, 
discretion of information on effectiveness, durability, and 
results may lead to unexpected problems 30.
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Conclusion
Our initial experience with general anesthesia and invasive 
monitoring proved to be an effective and efﬁ cient option, 
allowing strict hemodynamic control and early identiﬁ cation 
of problems during the procedure. The anesthetic complica-
tions were minor and easily treated; however, the event of 
surgical complication is potentially serious 10,19,22,38,40. Valve 
duration is still an important consideration in selecting pa-
tients for this type of valve implantation, particularly younger 
patients. Additional studies, greater experience, and longer 
follow-up are still needed to deﬁ ne the best technique to 
be adopted. 
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